Intelligent Bio Solutions Inc. (INBS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Intelligent Bio Solutions Inc. (INBS) Healthcare & Pipeline Overview

Intelligent Bio Solutions Inc. specializes in developing and commercializing non-invasive, real-time diagnostic solutions, including a saliva-based glucose biosensor for diabetes management. The company aims to disrupt traditional testing methods with its innovative biosensor platform, targeting point-of-care diagnostics and remote patient monitoring within the healthcare sector.

What Is the Investment Thesis for INBS?

Intelligent Bio Solutions Inc. presents a notable research candidate within the diagnostics sector, driven by its innovative approach to non-invasive monitoring. The company's Saliva Glucose Biosensor addresses a significant market need for pain-free diabetes management. Key value drivers include successful clinical validation and regulatory approval of the glucose biosensor, expansion of the biosensor platform to other diagnostic areas, and strategic partnerships for commercialization. The company's high beta of 4.24 suggests high volatility. The company's negative profit margin of -296.8% indicates it is not currently profitable. Upcoming catalysts include clinical trial results and potential FDA approvals for its biosensor products. The company's gross margin is 32.1%.

Based on FMP financials and quantitative analysis

INBS Key Highlights

• Intelligent Bio Solutions Inc. is focused on developing non-invasive, real-time monitoring and diagnostic tests.
• The company's lead product is the Saliva Glucose Biosensor, targeting the diabetes management market.
• The company is also developing a SARS-CoV-2 Biosensor to complement traditional virus detection tests.
• Intelligent Bio Solutions operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
• The company's gross margin is 32.1%.

Who Are INBS's Competitors?

INBS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are INBS's Key Strengths?

• Innovative biosensor technology platform.
• Focus on non-invasive diagnostics.
• Potential for real-time monitoring and rapid results.
• Addresses a significant market need for diabetes management and infectious disease testing.

What Are INBS's Weaknesses?

• Limited commercialization experience.
• Reliance on successful clinical validation and regulatory approvals.
• High beta indicates significant volatility.
• Negative profit margin.

What Could Drive INBS Stock Higher?

• Clinical trial results for the Saliva Glucose Biosensor.
• Regulatory submissions and potential FDA approvals for biosensor products.
• Expansion of the biosensor platform to new diagnostic areas.
• Strategic partnerships and collaborations with healthcare providers and diagnostic companies.

What Are the Key Risks for INBS?

• Financial-distress signal — its Altman Z-Score of -8.45 sits in the distress zone (elevated bankruptcy risk).
• Delays in clinical trials and regulatory approvals.
• Competition from established players in the diagnostics market.
• Technological obsolescence and the emergence of competing technologies.
• Dependence on successful commercialization of biosensor products.
• High beta indicates significant volatility.

What Are the Growth Opportunities for INBS?

• Expansion of the Saliva Glucose Biosensor: The market for glucose monitoring is substantial, with a global market size estimated at billions of dollars. Successful commercialization of the Saliva Glucose Biosensor could capture a significant share of this market. The company must achieve regulatory approvals and demonstrate clinical efficacy to penetrate the market. The timeline for market entry depends on clinical trial outcomes and regulatory processes, potentially within the next 2-3 years.
• Development of the SARS-CoV-2 Biosensor: With ongoing concerns about respiratory viruses, a rapid and accurate SARS-CoV-2 biosensor could address a critical need for point-of-care testing. The market for COVID-19 diagnostics remains significant, although it may evolve with changing pandemic dynamics. The company aims to position its biosensor as a complementary tool to existing RNA detection tests. The timeline for commercialization depends on regulatory approvals and validation studies.
• Broadening the Biosensor Platform: Expanding the biosensor platform to include other diagnostic modalities, such as biochemistry, immunology, tumor markers, and hormones, could significantly increase the company's market reach. Each of these diagnostic areas represents a substantial market opportunity. The company's ability to develop and validate new biosensor applications will be crucial for success. This expansion could occur over the next 3-5 years.
• Strategic Partnerships and Collaborations: Forming partnerships with healthcare providers, diagnostic companies, and pharmaceutical firms could accelerate the commercialization and adoption of Intelligent Bio Solutions' products. Strategic alliances can provide access to new markets, distribution channels, and technological expertise. The company's ability to forge successful partnerships will be essential for its long-term growth. These partnerships could materialize within the next 1-2 years.
• Geographic Expansion: Expanding into new geographic markets, particularly in regions with a high prevalence of diabetes and a growing demand for point-of-care diagnostics, could drive significant revenue growth. The company's initial focus is on the US market, but international expansion could follow. The timeline for geographic expansion depends on regulatory approvals and market entry strategies. This expansion could begin within the next 2-3 years.

What Opportunities Does INBS Have?

• Expansion into new diagnostic areas and geographic markets.
• Strategic partnerships with healthcare providers and diagnostic companies.
• Growing demand for point-of-care testing and remote patient monitoring.
• Potential for government funding and grants for innovative diagnostic technologies.

What Threats Does INBS Face?

• Competition from established players in the diagnostics market.
• Regulatory hurdles and lengthy approval processes.
• Technological obsolescence and the emergence of competing technologies.
• Uncertainty surrounding the long-term impact of the COVID-19 pandemic on diagnostic testing demand.

What Are INBS's Competitive Advantages?

• Proprietary biosensor technology platform.
• Focus on non-invasive diagnostics, offering a competitive advantage over traditional methods.
• Potential for strong intellectual property protection through patents and trade secrets.

What Does INBS Do?

Intelligent Bio Solutions Inc., formerly known as GBS Inc., was founded in 2016 and is headquartered in New York City. The company is a life sciences firm dedicated to the development of innovative, non-invasive diagnostic and monitoring solutions. Their primary focus is on creating real-time testing devices that can be used by patients and healthcare providers directly. The company's lead product is the Saliva Glucose Biosensor, an organic thin-film transistor designed to measure glucose levels in saliva, offering a pain-free alternative to traditional blood glucose monitoring for diabetes management. In addition to the glucose biosensor, Intelligent Bio Solutions is developing a SARS-CoV-2 Biosensor to complement existing virus detection tests. The company is also working on a broader biosensor platform that can accommodate various diagnostic modalities, including biochemistry, immunology, tumor markers, hormones, and nucleic acid testing. Intelligent Bio Solutions operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd. and aims to revolutionize point-of-care diagnostics and remote patient monitoring.

What Products and Services Does INBS Offer?

• Develop non-invasive, real-time monitoring and diagnostic tests.
• Create saliva-based glucose biosensors for diabetes management.
• Develop biosensors for SARS-CoV-2 detection.
• Offer a biosensor platform for various diagnostic modalities.
• Focus on point-of-care diagnostics and remote patient monitoring.
• Provide solutions for patients and healthcare practitioners.

How Does INBS Make Money?

• Develop and commercialize biosensor-based diagnostic products.
• Generate revenue through sales of biosensor devices and related consumables.
• Establish partnerships with healthcare providers and diagnostic companies for distribution.

What Industry Does INBS Operate In?

The medical diagnostics industry is experiencing rapid growth, driven by technological advancements, increasing prevalence of chronic diseases, and a growing demand for point-of-care testing. The market for glucose monitoring devices is substantial, with a significant portion seeking less invasive methods. Intelligent Bio Solutions aims to capitalize on this trend with its saliva-based glucose biosensor. The competitive landscape includes established players in the diabetes care market, as well as emerging companies developing novel diagnostic technologies. The industry is characterized by stringent regulatory requirements and a focus on accuracy, reliability, and ease of use.

Who Are INBS's Key Customers?

• Patients with diabetes seeking non-invasive glucose monitoring.
• Healthcare providers requiring point-of-care diagnostic solutions.
• Diagnostic laboratories and research institutions.
• Individuals needing rapid SARS-CoV-2 testing.

How Intelligent Bio Solutions Inc. Is Valued

Intelligent Bio Solutions Inc. carries a market capitalization of $1.27M, placing it in the micro-cap category. Relative to its peer group, INBS's quantitative score of 18/100 is below the peer average of 56/100.

Key Financial Metrics

Return on assets is -78.1%, showing how much profit it generates from its asset base. A current ratio of 2.11 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 4/9Financial Health

Intelligent Bio Solutions Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -8.45 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Intelligent Bio Solutions Inc. revenue of about $4.3M for fiscal 2026, with EPS near $-3.42.

INBS Financials

INBS Latest News

INBS Analyst Consensus

INBS MoonshotScore

Common Questions About INBS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources